Mon.Jul 08, 2024

article thumbnail

Opinion: EcoHealth Alliance: Covid’s anti-science mob extracting its pound of flesh

STAT

Imagine this post-9/11 scenario: A New York City fire company is forced to shut down and lay off its firefighters because some Americans believe a bizarre conspiracy theory that this fire company brought down the World Trade Center towers. A Covid-19 version of this freakish tale is happening today. Instead of a fire company, the conspiracy gang is targeting an important, successful, decades-old nonprofit organization that researches viral epidemics and tries to predict and forestall future 

363
363
article thumbnail

The FDA pushes concrete plans to further diversity in clinical trials

PharmaVoice

The long-awaited guidance offers a more detailed road map for pharma.

230
230
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New study sparks debate about whether H5N1 virus in cows is adapted to better infect humans

STAT

A study published Monday provides new evidence that the H5N1 virus currently causing an outbreak of bird flu in U.S. dairy cattle may be adapted to better infecting humans than other circulating strains of the virus, a result that is already courting controversy among the world’s leading flu researchers. Across the globe, different influenza viruses are constantly circulating in many different kinds of animals.

363
363
article thumbnail

Coloplast launches digital leakage notification system Heylo for stoma patients

Pharma Times

More than 176,000 people in the UK are living with a stoma, according to NHS data

154
154
article thumbnail

Navigating Payroll Compliance: Future-Proofing Payroll in an Evolving Regulatory Landscape

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

article thumbnail

Opinion: The ethical implications of Elon Musk’s unorthodox approach to medical science

STAT

Medical milestones broadcast via tweet. Scientific progress revealed via live YouTube demo. Teasers for updates followed by a livestream from a patient’s home. These aren’t the latest social media influencer tactics, but the way Neuralink, Elon Musk’s neurotechnology company, has disseminated information about its medical research.

article thumbnail

Mission awarded $5.2m to advance potential Parkinson’s treatment

Pharma Times

The progressive neurodegenerative condition affects around 153,000 people in the UK

138
138

More Trending

article thumbnail

Lilly to buy Morphic in $3B bet on inflammation drug

BioPharma Dive

The deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel disease.

120
120
article thumbnail

Bird flu snapshot: Live H5N1 virus grown from raw milk samples as Delaware moves to legalize its sale

STAT

Bird flu snapshot: This is the latest installment in a series of regular updates on H5N1 avian flu that STAT is publishing on Monday mornings. To read future updates, you can also subscribe to STAT’s Morning Rounds newsletter. Last week, following an unusually udder pun-laden discussion , lawmakers in Delaware voted to become the latest state to legalize the sale of raw milk.

345
345
article thumbnail

A London biotech raises $114M to hone a new ADC payload

BioPharma Dive

Myricx Bio is developing a type of payload that it thinks could work in tumors resistant to the toxins contained in ADCs like Enhertu and Trodelvy.

117
117
article thumbnail

STAT+: Biden administration appeals jury finding in battle over patents for HIV prevention pills

STAT

The Biden administration has appealed a decision in which a federal court jury last year sided with Gilead Sciences over the rights to a pair of groundbreaking HIV pills — and at least $1 billion in royalties may be at stake. At issue is a battle over patents for Truvada and a newer, upgraded version version called Descovy — two highly effective and lucrative medications — as well as the role played by the federal government in making it possible to prevent transmission of a

332
332
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Study finds GLP-1 drugs may cut obesity-related cancers

pharmaphorum

GLP-1 agonists like Novo Nordisk's Ozempic reduce the risk of 10 of 13 cancers associated with obesity in an observational study.

114
114
article thumbnail

STAT+: South Africa and J&J reach a deal to widen access to a key tuberculosis treatment

STAT

South African antitrust authorities ended an investigation into Johnson & Johnson and its Janssen subsidiary over “excessive pricing” of a lifesaving tuberculosis drug after the companies took steps to lower the cost and widen access to the medicine. In a brief statement , the Competition Commission explained that J&J and Janssen agreed not to enforce a so-called secondary patent on bedaquiline, which is also sold under the brand name Sirturo, a step that makes it possible

308
308
article thumbnail

Lilly scores against Novo Nordisk in weight loss contest

pharmaphorum

An observational study has suggested that Lilly’s tirzepatide is better at achieving weight loss than Novo Nordisk's semaglutide

111
111
article thumbnail

STAT+: AI leads the way as health tech funding inches toward a post-pandemic stability

STAT

Funding for health tech startups in the first half of 2024 remained far below the high levels seen immediately after the Covid-19 pandemic, but several indicators suggest stability — and maybe even a brewing comeback for the sector. Health tech startups raised $5.7 billion in the first half of the year, putting them on pace to just exceed the $10.7 billion total raised in 2023, according to a report from Rock Health , which invests in companies and provides advisory services.

275
275
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Lilly swoops on Morphic to claim IBD drug candidate

pharmaphorum

Eli Lilly boosts its inflammatory bowel disease pipeline with a $3.

111
111
article thumbnail

STAT+: Pulling back the curtain on psychiatric hospital joint ventures

STAT

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. Lifting the veil on psychiatric hospital joint ventures Nonprofit hospital systems are opening psychiatric hospitals to help the growing number of people suffering from mental  health  problems.

Hospitals 266
article thumbnail

Myricx raises £90m after pivot to ADCs for cancer

pharmaphorum

Myricx Bio taps into the red-hot interest in companies working on antibody-drug conjugates (ADCs) for cancer, raising £90m in its Series A

111
111
article thumbnail

STAT+: Eli Lilly to acquire Morphic for $3.2 billion

STAT

Eli Lilly said Monday it will acquire Morphic Holding, a biotech developing a treatment for inflammatory bowel disease. Lilly will pay about $3.2 billion to buy the Waltham, Mass.-based company. That translates to $57 per share, a premium of roughly 79% from Morphic’s Friday closing price. Morphic’s lead candidate, MORF-057, is an oral small molecule that blocks α4β7 integrin.

265
265
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Healthcare report finds declining public trust in institutions

pharmaphorum

A recent healthcare report conducted by Edelman reveals a concerning trend of declining public trust in healthcare institutions. Explore the key findings and implications in this comprehensive analysis.

110
110
article thumbnail

The biotech news you missed this week

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello! Hope your weekend was a blissful one. Today, we talk about AbbVie’s outsize marketing spend, see how GLP-1s are impacting cancer rates, and more.

article thumbnail

Ligand to buy Apeiron; Roche reports another TIGIT setback

BioPharma Dive

Acquiring Apeiron will hand Ligand rights to royalties on sales of the neuroblastoma drug Qarziba. Elsewhere, Aerovate said it’s considering strategic alternatives and CSL reported a notable milestone.

108
108
article thumbnail

STAT+: Pharmalittle: We’re reading about AbbVie spending on doctors, a new Lilly deal, and more

STAT

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of phone calls, online meetings, and deadlines has returned. But you knew this would happen, yes? After all, the world — such as it is — continues to spin. So we will make an effort to nudge it in a better direction by brewing a few cups of stimulation.

article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Myricx Bio gains $114m in Series A round to develop NMTi-ADCs

Pharmaceutical Technology

Myricx Bio has secured £90m ($114m) in its Series A financing round to propel its NMTi-ADC therapeutics into the clinical development stage.

105
105
article thumbnail

H.E.L Group appoints Dr Yih-Shing Duh as Chief Scientific Advisor

Express Pharma

H.E.L Group, a global developer and manufacturer of innovative laboratory tools for process optimisation, safety, and scale-up, announced the appointment of Dr Yih-Shing Duh as Chief Scientific Advisor. Bringing over 30 years of experience in thermal safety, Professor Duh will support the continued development of H.E.L’s comprehensive portfolio of battery calorimeters.

105
105
article thumbnail

As IARC uprates talc cancer risk, will J&J be affected?

pharmaphorum

IARC has published a new assessment of talc’s potential to cause cancer, concluding that is it ‘probably carcinogenic’ to humans

105
105
article thumbnail

Industry reports 76 deals worth $5B in June 2023: GlobalData

Express Pharma

In June 2024, the pharma and healthcare industry reported 76 deals worth $5B, compared to the last 12-month (June 2023 to May 2024) average of 95 deals worth $19B. Shanghai Fosun Pharmaceutical to acquire the remaining stake in Shanghai Henlius Biotech, a biopharmaceutical company, for a consideration of approximately $692.5 million; NewGenIvf Group, to acquire COVIRIX Medical, a clinical-stage pharmaceutical company developing novel antiviral therapies for $617.3 million; and Cycle Pharmaceutic

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Could Spain’s Grifols be heading for de-listing?

pharmaphorum

The family that owns Spanish pharma Grifols and private equity firm Brookfield may take the company private in a deal worth around €5.

103
103
article thumbnail

GSK and MVV launch malaria medicine in Brazil and Thailand

Pharmaceutical Technology

GSK and MMV have announced the launch of tafenoquine to prevent the relapse of P. vivax malaria in Brazil and Thailand.

102
102
article thumbnail

Pharma industry experts eye budget boost for innovation and global ambitions

Express Pharma

Dr Satish Wagh, Chairman & Managing Director, Supriya Lifescience “As we approach the Union Budget for 2024-25, the pharmaceutical and healthcare industry holds high expectations for continued support and facilitation from the government. The Indian pharmaceutical industry, valued at $50 billion and contributing around 1.72 per cent to the national GDP, plays a pivotal role in both domestic and global markets.

article thumbnail

Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition

Pharmaceutical Technology

Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials, with data in ulcerative colitis expected next year.

98
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.